Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Current trial landscape of IgA nephropathy therapy.
Current trial landscape of IgA nephropathy therapy. Med (New York, N.Y.) Kim, J., Kamal, F., Lafayette, R. 2026; 7 (1): 100940Abstract
IgA nephropathy is in a transformative era, with disease-targeted therapies advancing beyond supportive care. This Trial Watch summarizes recent clinical progress in complement inhibition, endothelin receptor antagonism, and B cell and plasma-cell-directed strategies, highlighting promising reductions in proteinuria, preservation of renal function, and the emerging framework for precision, biomarker-guided treatment.
View details for DOI 10.1016/j.medj.2025.100940
View details for PubMedID 41519110